KUALA LUMPUR, June 13 (Bernama) -- Crown Bioscience, a global drug discovery and development services company has announced four new pre-clinical translational NASH models in development.
NASH is a degenerative liver disease that affects up to 12 per cent of the adult population worldwide and without treatment, is expected to become the leading cause for liver transplants by 2020.
CrownBio is committed to the NASH drug development community through continued research and development of translatable preclinical NASH models. This dedicated investment will result in the availability of four new models over the next 12 months.
The models comprise chemically-enhanced murine model using carbon tetrachloride; modified diet model which more closely mimic a western diet and exacerbates fibrosis; accelerated diet-induced murine model; and, accelerated diet-induced NHP model.
These models will join the existing CrownBio NASH platform, according to a statement.
A webinar that presents solutions to the challenges associated with pre-clinical modelling of NASH will be host to support International NASH Day 2019. CrownBio will also donate US$25 for each person attending the webinar to the Global Liver Institute. (US$1 = RM 4.16)
-- BERNAMA
No comments:
Post a Comment